Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) was submitted on July 3, 2023, for the month of July 2023. The filing addresses a corporate governance matter regarding the selection of a new independent registered public accounting firm.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a report on auditor selection and does not contain financial performance data.
Material Changes
The primary material change disclosed is the proposed replacement of the Company's independent registered public accounting firm. The Audit Committee recommended appointing Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) to replace the current firm, Kost Forer Gabbay & Kasierer (a member of Ernst & Young Global). This change is subject to shareholder approval at the upcoming annual general meeting.
Guidance, Outlook, and Risks
Management commentary confirms that during the tenure of the outgoing auditor (covering fiscal years 2021 and 2022), there were no disagreements regarding accounting principles, financial statement disclosures, or auditing scope. Furthermore, no "reportable events" as defined in Regulation S-K occurred. The filing does not provide specific financial guidance, operational outlook, or new risk factors beyond the standard transition of audit services.
Key Facts for Investor Verification
- Shareholder approval is required at the upcoming annual general meeting to finalize the appointment of Kesselman & Kesselman.
- The outgoing auditor, Kost Forer Gabbay & Kasierer, will conclude its engagement at the end of the shareholder meeting.
- No accounting disagreements or reportable events were identified during the previous auditor's tenure.
- The filing contains no financial results or operational metrics for the period.